Cargando…

Engineering antibody-like inhibitors to prevent and treat HIV-1 infection

PURPOSE OF REVIEW: Here we discuss recently developed HIV-1 entry inhibitors that can target multiple epitopes on the HIV-1 envelope glycoprotein (Env), with an emphasis on eCD4-Ig. Some of these inhibitors are more potent and broader than any single antibody characterized to date. We also discuss t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gardner, Matthew R., Farzan, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	HIV AND NOVEL STRATEGIES FOR INDUCTION OF BROAD NEUTRALIZING ANTIBODIES FOLLOWING VACCINATION: Edited by Ralf Wagner
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389584/ https://www.ncbi.nlm.nih.gov/pubmed/28422793 http://dx.doi.org/10.1097/COH.0000000000000367

Ejemplares similares

Lessons learned from human HIV vaccine trials
por: Pollara, Justin, et al.
Publicado: (2017)

Stabilized HIV-1 envelope glycoprotein trimers for vaccine use
por: Medina-Ramírez, Max, et al.
Publicado: (2017)

Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages
por: Guo, Li, et al.
Publicado: (2023)

Cross-reactive antibodies binding to H4 hemagglutinin protect against a lethal H4N6 influenza virus challenge in the mouse model
por: Amanat, Fatima, et al.
Publicado: (2019)

Non-neutralizing monoclonal antibody targeting VP2 EF loop of Coxsackievirus A16 can protect mice from lethal attack via Fc-dependent effector mechanism
por: Du, Ruixiao, et al.
Publicado: (2022)

Protection against homo and hetero-subtypic inﬂuenza A virus by optimized M2e DNA vaccine
por: Yao, Yanfeng, et al.
Publicado: (2019)

Bivalent vaccines effectively protect mice against influenza A and respiratory syncytial viruses
por: Raman, Sathya N. Thulasi, et al.
Publicado: (2023)

Coronavac inactivated vaccine triggers durable, cross-reactive Fc-mediated phagocytosis activities
por: Wang, Lili, et al.
Publicado: (2023)

Recovering vaccine coverage lost due to the COVID-19 pandemic()
por: Moraga-Llop, F.A., et al.
Publicado: (2020)

Adenoviral vector-based COVID-19 vaccines-associated cerebral venous sinus thromboses: Are those adverse events related to the formation of neutrophil extracellular traps?
por: Simka, Marian
Publicado: (2022)

Selection of new COVID-19 genotypes following mass vaccination: The Rotavirus model
por: Lapolla, Pierfrancesco, et al.
Publicado: (2022)

Mass vaccinations against COVID-19 through the use of technologies for the management of appointment scheduling and data of large volumes of vaccinated()
por: Rodas-Martinez, Alicia K., et al.
Publicado: (2022)

Establishment of the 1st Chinese national standard for CA6 neutralizing antibody
por: Wang, Yiping, et al.
Publicado: (2023)

Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial
por: López, Pio, et al.
Publicado: (2023)

Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage
por: Wagh, Kshitij, et al.
Publicado: (2023)

Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV
por: Zolla-Pazner, Susan, et al.
Publicado: (2019)

A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal
por: Chaudhary, Shipra, et al.
Publicado: (2023)

The applications of animal models in phage therapy: An update
por: Mehmood Khan, Fazal, et al.
Publicado: (2023)

Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial
por: Galgani, Ilaria, et al.
Publicado: (2023)

Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10–50 years old: Randomized, blinded, parallel controlled phase III clinical study
por: Huang, Xiaoyuan, et al.
Publicado: (2023)

Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally
por: Liao, Yun, et al.
Publicado: (2023)

Analysis and prediction of the incidence and prevalence trends of gonorrhea in China
por: Chen, Xueya, et al.
Publicado: (2023)

An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life
por: Patel, Sanjay S., et al.
Publicado: (2023)

Advancements in the development of nucleic acid vaccines for syphilis prevention and control
por: Li, Sijia, et al.
Publicado: (2023)

Acceptability for the influenza virus vector COVID-19 vaccine for intranasal spray: A cross-sectional survey in Beijing, China
por: Ma, Yuan, et al.
Publicado: (2023)

Challenges in development of vaccines directed toward antimicrobial resistant bacterial species
por: Brazzoli, Michela, et al.
Publicado: (2023)

Monoclonal Antibody Against Stromal Cell-Derived Factor 2
Publicado: (2020)

Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms
por: Brouwer, Philip J.M., et al.
Publicado: (2019)

Control of Interferon Production in Rabbit Cells Treated with Poly I:C
por: Armstrong, John A.
Publicado: (1970)

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
por: Huang, Yunda, et al.
Publicado: (2021)

Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development
por: Haynes, Barton F., et al.
Publicado: (2023)

Modulation of HIV-1 immunity by adjuvants
por: Moody, M. Anthony
Publicado: (2014)

Double-Stranded Polynucleotides as Interferon Inducers
por: Field, A. K., et al.
Publicado: (1970)

Cellular Mechanisms of Interferon Production
por: Vilček, Jan
Publicado: (1970)

The Uptake of a Labeled Double-Stranded Polynucleotide by Cultured Rabbit Kidney Cells: An Electron Microscopic Study
por: Prose, Philip H., et al.
Publicado: (1970)

Circulating Interferon Production in the Mouse : Origin and nature of cells involved and influence of animal genotype
por: De Maeyer, Edward, et al.
Publicado: (1970)

Molecular Aspects of Interferon Induction by Viruses
por: Burke, D. C.
Publicado: (1970)

Interferon Induction by Viruses
por: Lockart, Royce Z.
Publicado: (1970)

Nonviral Interferon Inducers
por: Merigan, Thomas C., et al.
Publicado: (1970)

Interferon Production by Nonviral Stimuli of Microbial Origin
por: Youngner, Julius S.
Publicado: (1970)

Cannot write session to /tmp/vufind_sessions/sess_fgqapud6f00mm45sd60ub8ut2k